A Phase 1 interventional study of NGM120 and Placebo in Cachexia, sponsored by NGM Biopharmaceuticals, Inc. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-20.
Sponsored by NGM Biopharmaceuticals, Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Cachexia with a site in Australia — 3 open to participants now, 3 under way, 1 of them phase 3. Cachexia · Australia.
Among the 11 studies in Cachexia with a site in Australia, this one is the 7th largest by enrollment, is the only one that started in 2018, is one of 2 in phase 1, and was the 5th registered.
331 studies on the registry are indexed under Cachexia; 74 are open to participants now.
Browse Cachexia studies →3 of the 11 studies in Cachexia with a site in Australia are open now. Recruiting first, the newest first:
Dartsbio Pharmaceuticals Ltd. · Sites in Australia
Ages 18+
Pfizer · Sites in Australia, United States, Belgium and 18 more countries
Ages 18+
Olivia Newton-John Cancer Research Institute · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 55 Cachexia studies recruiting now, 32 (58%) set no upper age limit and 14 (25%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 4
First in 2008; this study’s year is marked. 1 started in 2018.
This study's enrollment of 92 is above the median of 74 across 226 interventional studies indexed under Cachexia.
Median enrollment 124 across the 11 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 8 most frequent:
NGM Biopharmaceuticals, Inc is the lead sponsor of 26 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
NGM Biopharmaceuticals, Inc has 1 study filed under Cachexia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Cachexia with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Dose
Biological: NGM120
Single Dose
Other: Placebo
Multiple Dose
Biological: NGM120
Multiple Dose
Other: Placebo
Subcutaneous Injection
Subcutaneous Injection
Part A Arm-Single Dose: Treatment Emergent Adverse events
Percentage of total subjects with Treatment Emergent Adverse event
Time frame: 28 days
Part B Arm-Multiple Dose: Treatment Emergent Adverse events
Percentage of total subjects with Treatment Emergent Adverse event
Time frame: 84 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2018 to primary completion in Jan 2019, 11 months.
Of 21 phase 1 interventional studies under Cachexia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 11 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anti-GFRAL Monoclonal Antibody NGM120